Recruiting

MyeloGen Gene Panel

Sponsor:

Christopher Reilly

Code:

NCT07112287

Conditions

Myeloid Malignancy

Genetic Predisposition to Disease

Myeloid Hematological Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MyeloGen Gene Panel

Study Details

Brief summary:

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Conditions

Myeloid Malignancy

Genetic Predisposition to Disease

Myeloid Hematological Malignancies

Study ID

NCT07112287

Start date

Nov 10, 2025

Status verified date

Apr, 2026

Completion date

Apr 1, 2033

Anticipated

Primary completion date

Apr 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age of 18 years or older
  • Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
  • Ability to understand and provide a signed and completed consent document in English.

Exclusion Criteria:

  • Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
  • Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies

Study Design

Enrollment

200 participants

Anticipated

Intervention Model

Single group

Primary purpose

Screening

Interventions and Outcome Measures

Arms

experimental: MyeloGen Germline Testing Group

Enrolled participants will complete:

  • Baseline visit with questionnaires, educational video, and punch skin biopsy
  • Negative genetic test results notification via mail
  • Positive genetic results will be followed up by an appointment with a genetic counselor or physician
  • Post-results questionnaires
  • Follow up via medical records for up to 2 years from time of study consent.

Interventions

MyeloGen Gene Panel

The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

Primary outcome measure

  • Successful Completion Rate [ Time Frame: Up to 10 weeks ]

Central Contacts and Locations

Central contacts

Christopher R Reilly, MD

407-443-6243Christopherr_reilly@dfci.harvard.edu

Locations

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Christopher R Reilly, MD

407-443-6243christopherr_reilly@dfci.harvard.edu

Principal Investigator:

Christopher R Reilly, MD

More Information

Sponsor

Christopher Reilly

Last update posted

Apr 24, 2026

Last verified

Apr, 2026

Keywords

  • Myeloid Malignancies
  • Genetic Predisposition to Disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Christopher Reilly on 2026-04-24.